ADC Development Services Targeting FLT3

As a novel targeted therapy for cancers, antibody-drug conjugates (ADCs) are displaying great potential and promising. Various ADCs against different targets are developed actively in recent years, which need high-quality material such as antibody and linker-payload and optimal conjugation strategy. Creative Biolabs is a leader in the field of antibody production and bio-conjugation for more than ten years, we offer a full range of ADCs design and construction services targeting the specific FLT3 protein, from materials preparation to final product characterization.

Introduction of FLT3

FMS-like tyrosine kinase 3 (FLT3), also known as CD135 (cluster of differentiation antigen 135), is a receptor tyrosine kinase. It is encoded by the FLT3 gene, which is mainly expressed by the immature hematopoietic cells. FLT3 contains five extracellular immunoglobulin-like domains, an extracellular domain, a transmembrane domain, a juxtamembrane domain and a tyrosine-kinase domain. FLT3 plays a critical role in the formation and growth of new blood cells, which also is involved in the normal development of stem cells and the immune system. Mutations of FLT3 can lead to the overexpression of the protein and cause the body to make excess abnormal white blood cells, which then induces some leukemia diseases, such as the acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Therefore, FLT3 is an attractive therapeutic target in the therapy for patients with leukemia.

Fig.1 Schematic illustration of aberrant and potentially druggable signaling in leukemic blasts leading to cellular proliferation and survival advantage in AML.^1,2

What Can We Do for You?

ADCs are known to be potent and powerful tumor-killing agents with targeted therapy and minimal side effects for cancer patients. Several effective ADCs have been developed for the AML therapy based on specific targets. With dedicated commitment to the scientific community, Creative Biolabs has perfected our technical pipelines in the development of diverse ADCs. Our featured ADCs services include ADC Antibody Screening, DrugLnk™ Custom Synthesis, Antibody Design and Conjugation, ADC in vitro Analysis and ADC in vivo Analysis. We would like to share our knowledge and passion in this field to promote your ADC development. Please contact us for more information and a detailed quote.

References

1. Bohl, Stephan R., Lars Bullinger, and Frank G. Rücker. "New targeted agents in acute myeloid leukemia: new hope on the rise." International journal of molecular sciences 20.8 (2019): 1983.
2. Distributed under Open Access License CC BY 4.0, without modification.